This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Pramlintide
Synthetic Amylin Analog
/WHAT_IT_IS
Pramlintide is a synthetic analog of human amylin, a beta-cell co-secreted peptide with insulin. In research settings it’s used to study postprandial glucose control, gastric emptying, satiety, and glucagon suppression.
/USAGE
Investigated as an adjunct to mealtime insulin to model reductions in postprandial hyperglycemia and appetite, and to explore amylin physiology in metabolic studies.
/MECHANISM_OF_ACTION
Activates amylin receptors to slow gastric emptying, suppress inappropriate postprandial glucagon secretion, and enhance satiety—thereby reducing postprandial glucose excursions.
Reported Benefits
- +Reduces postprandial glucose excursions
- +Decreases glucagon surge after meals
- +Slows gastric emptying
- +May reduce appetite and caloric intake
Reported Side Effects
- −Nausea, vomiting, abdominal discomfort
- −Decreased appetite
- −Injection-site reactions
- −Hypoglycemia when used with insulin (requires mealtime insulin dose reduction)
- −Boxed warning: severe insulin-induced hypoglycemia risk, especially within 3 hours post-dose
/STACKED_WITH
/RESEARCH_NOTES
Often studied in type 1 and insulin-treated type 2 diabetes models to examine postprandial control. Titrate cautiously; initial mealtime insulin dose reductions are standard in protocols. Avoid in severe gastroparesis models.
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.